G
Geoffrey R. Oxnard
Researcher at Foundation Medicine
Publications - 325
Citations - 18990
Geoffrey R. Oxnard is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 54, co-authored 245 publications receiving 14325 citations. Previous affiliations of Geoffrey R. Oxnard include Dana Corporation & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress,Cloud P. Paweletz,Enriqueta Felip,Byoung Chul Cho,Daniel Stetson,Brian Dougherty,Zhongwu Lai,Aleksandra Markovets,Ana Vivancos,Yanan Kuang,Dalia Ercan,Sarah E Matthews,Mireille Cantarini,J. Carl Barrett,Pasi A. Jänne,Geoffrey R. Oxnard +15 more
TL;DR: Analysis of cell-free plasma DNA collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD 9291 provides insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291.
Journal ArticleDOI
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
Geoffrey R. Oxnard,Cloud P. Paweletz,Yanan Kuang,Stacy L. Mach,Allison O'Connell,Melissa M. Messineo,Jason J. Luke,Mohit Butaney,Paul Kirschmeier,David M. Jackman,Pasi A. Jänne +10 more
TL;DR: Serial quantification of plasma genotype allows noninvasive assessment of response and resistance, including detection of resistance mutations up to 16 weeks before radiographic progression, and demonstrates assay qualities that could allow effective translation into a clinical diagnostic.
Journal ArticleDOI
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard,Kenneth S. Thress,Ryan S. Alden,Rachael Lawrance,Cloud P. Paweletz,Mireille Cantarini,James Chih-Hsin Yang,J. Carl Barrett,Pasi A. Jänne +8 more
TL;DR: In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay, which suggests that, upon availability of validated plasma T790m assays, some patients could avoid a tumor biopsy forT790M genotyping.
Journal ArticleDOI
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
TL;DR: Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.
Journal ArticleDOI
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Lecia V. Sequist,Jean-Charles Soria,Jonathan W. Goldman,Heather A. Wakelee,Shirish M. Gadgeel,Andrea Varga,Vassiliki A. Papadimitrakopoulou,Benjamin Solomon,Geoffrey R. Oxnard,Rafal Dziadziuszko,Dara L. Aisner,Robert C. Doebele,Cathy Galasso,Edward B. Garon,Rebecca S. Heist,Jennifer A. Logan,Joel W. Neal,Melody A. Mendenhall,Suzanne Nichols,Zofia Piotrowska,Antoinette J. Wozniak,Mitch Raponi,Chris Karlovich,Sarah Jaw-Tsai,Jeffrey D. Isaacson,Darrin Despain,Shannon Matheny,Lindsey Rolfe,Andrew R. Allen,D. Ross Camidge +29 more
TL;DR: Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation and the only common dose-limiting adverse event was hyperglycemia.